Randomized placebo-controlled dose-ranging and pharmacodynamics study of roxadustat (FG-4592) to treat anemia in nondialysis-dependent chronic kidney disease (NDD-CKD) patients

per Besarab, Anatole, Provenzano, Robert, Hertel, Joachim, Zabaneh, Raja, Klaus, Stephen J., Lee, Tyson, Leong, Robert, Hemmerich, Stefan, Yu, Kin-Hung Peony, Neff, Thomas B.
Publicat a Nephrol Dial Transplant (2015)

Roxadustat (FG-4592): Correction of Anemia in Incident Dialysis Patients

per Besarab, Anatole, Chernyavskaya, Elena, Motylev, Igor, Shutov, Evgeny, Kumbar, Lalathaksha M., Gurevich, Konstantin, Chan, Daniel Tak Mao, Leong, Robert, Poole, Lona, Zhong, Ming, Saikali, Khalil G., Franco, Marietta, Hemmerich, Stefan, Yu, Kin-Hung Peony, Neff, Thomas B.
Publicat a J Am Soc Nephrol (2016)

Oral Hypoxia–Inducible Factor Prolyl Hydroxylase Inhibitor Roxadustat (FG-4592) for the Treatment of Anemia in Patients with CKD

per Provenzano, Robert, Besarab, Anatole, Sun, Chao H., Diamond, Susan A., Durham, John H., Cangiano, Jose L., Aiello, Joseph R., Novak, James E., Lee, Tyson, Leong, Robert, Roberts, Brian K., Saikali, Khalil G., Hemmerich, Stefan, Szczech, Lynda A., Yu, Kin-Hung Peony, Neff, Thomas B.
Publicat a Clin J Am Soc Nephrol (2016)